Bitcoin groundbreakers share personal stories of how Bitcoin is changing lives for the better. Host Mauricio Di Bartolomeo, co-founder and CSO of Ledn, speaks with leading Bitcoin voices, entrepreneurs, and human rights advocates to hear their unique journey and practical real-world examples of how Bitcoin has made a positive impact in their lives. Brought to you by Ledn, a leading financial services company built for Bitcoin & digital assets. Ledn offers a suite of lending, saving and tradi ...
…
continue reading
コンテンツは Proactive Investors によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Proactive Investors またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Player FM -ポッドキャストアプリ
Player FMアプリでオフラインにしPlayer FMう!
Player FMアプリでオフラインにしPlayer FMう!
Tonix Pharma enrols first patient in key TNX-1300 study for intoxication
Manage episode 435576000 series 2891889
コンテンツは Proactive Investors によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Proactive Investors またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Tonix Pharmaceuticals CEO Dr Seth Lederman tells Proactive's Stephen Gunnion the first patient has been enrolled in the Phase 2 CATALYST study involving TNX-1300, a novel therapy aimed at reversing the effects of cocaine intoxication. Lederman highlighted that this study, supported by the National Institute on Drug Abuse (NIDA), is a significant step forward in addressing the urgent issue of cocaine-related emergencies, which currently lack effective direct treatments. Lederman explained that TNX-1300 works by breaking down cocaine in the bloodstream, rendering it inactive and mitigating its dangerous effects. He also discussed the previous Phase 2A study where TNX-1300 showed compelling results in reversing cocaine's impact in a controlled laboratory setting. The Phase 2B study, according to Lederman, could yield results as soon as 2025, with potential pivotal implications for the treatment's future. Lederman also touched on the broader issue of cocaine intoxication in the US, noting that it often involves mixed drugs, such as cocaine combined with fentanyl, which complicates treatment and increases risks. The interview concluded with Lederman expressing optimism about the study’s progress and its potential to fill a critical gap in emergency care. Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel, and enable notifications for future content. #TonixPharmaceuticals #CocaineAddiction #TNX1300 #ClinicalTrial #DrugAbuse #SethLederman #FDAApproval #PharmaNews #ProactiveInvestors #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
608 つのエピソード
Manage episode 435576000 series 2891889
コンテンツは Proactive Investors によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Proactive Investors またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Tonix Pharmaceuticals CEO Dr Seth Lederman tells Proactive's Stephen Gunnion the first patient has been enrolled in the Phase 2 CATALYST study involving TNX-1300, a novel therapy aimed at reversing the effects of cocaine intoxication. Lederman highlighted that this study, supported by the National Institute on Drug Abuse (NIDA), is a significant step forward in addressing the urgent issue of cocaine-related emergencies, which currently lack effective direct treatments. Lederman explained that TNX-1300 works by breaking down cocaine in the bloodstream, rendering it inactive and mitigating its dangerous effects. He also discussed the previous Phase 2A study where TNX-1300 showed compelling results in reversing cocaine's impact in a controlled laboratory setting. The Phase 2B study, according to Lederman, could yield results as soon as 2025, with potential pivotal implications for the treatment's future. Lederman also touched on the broader issue of cocaine intoxication in the US, noting that it often involves mixed drugs, such as cocaine combined with fentanyl, which complicates treatment and increases risks. The interview concluded with Lederman expressing optimism about the study’s progress and its potential to fill a critical gap in emergency care. Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel, and enable notifications for future content. #TonixPharmaceuticals #CocaineAddiction #TNX1300 #ClinicalTrial #DrugAbuse #SethLederman #FDAApproval #PharmaNews #ProactiveInvestors #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
608 つのエピソード
Tutti gli episodi
×プレーヤーFMへようこそ!
Player FMは今からすぐに楽しめるために高品質のポッドキャストをウェブでスキャンしています。 これは最高のポッドキャストアプリで、Android、iPhone、そしてWebで動作します。 全ての端末で購読を同期するためにサインアップしてください。